Novartis to Acquire Myricx Bio for Up to $1.5 Billion to Bolster Next-Gen ADC Pipeline
Novartis is gaining B7-H3 and HER2 ADCs with innovative NMTi technology designed to overcome cancer resistance.
/ 1648 items
#XY↓
Seer CEO Omid Farokhzad Makes Unsolicited $2.45/Share Offer to Buy the Company
The Board will form a Special Committee to evaluate the offer.
United Therapeutics Acquires Thymmune Therapeutics for $300M to Advance Thymus-Based Regenerative Therapies
The deal accelerates United Therapeutics’ pipeline in immune restoration and transplant tolerance.
Arcturus Therapeutics Shares Surge on Thermo Fisher Collaboration for Cystic Fibrosis mRNA Therapy
Arcturus teams up with Thermo Fisher to develop a new cystic fibrosis mRNA drug, boosting shares on hopes for faster progress.
TD Cowen Boosts TransMedics Price Target to $120 on Strong Transplant Growth
Accelerating U.S. heart, liver & lung transplants plus strong flight data signal major growth ahead.
Short Seller Culper Attacks Tarsus Pharmaceuticals Over XDEMVY Market Size
Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.